| 2025 | 2024 | 2023 | 2022 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 173,8 M € | +4.7% | 166,1 M € | -1.5% | 168,6 M € | -4.6% | 176,8 M € | +72.1% | 102,7 M € | +15.7% | 88,7 M € | +18.2% | 75,1 M € | +12.6% | 66,7 M € | +4.7% | 63,7 M € | +2.6% | 62,1 M € | +11.3% | 55,8 M € | -2.2% | 57,1 M € | -2.2% | 58,4 M € | +17.2% | 49,8 M € | +11.2% | 44,8 M € | -9.2% | 49,3 M € | +4.6% | 47,2 M € | +19.0% | 39,6 M € | |
| EBITDA | 12,8 M € | +3.2% | 12,4 M € | +148.0% | 5,0 M € | -5.7% | 5,3 M € | -10.1% | 5,9 M € | +116.7% | 2,7 M € | -35.2% | 4,2 M € | +1054.7% | 362,5 k € | +109.5% | -3,8 M € | -300.2% | 1,9 M € | +297.0% | 478,0 k € | +522.9% | -113,0 k € | -111.4% | 989,9 k € | -14.1% | 1,2 M € | -29.3% | 1,6 M € | -5.1% | 1,7 M € | -31.6% | 2,5 M € | +45.1% | 1,7 M € | |
| Operating profit | 8,9 M € | +17.1% | 7,6 M € | +557.9% | 1,2 M € | -45.0% | 2,1 M € | -35.1% | 3,2 M € | +773.0% | 369,3 k € | -78.5% | 1,7 M € | +185.5% | -2,0 M € | +58.3% | -4,8 M € | -787.5% | 702,4 k € | +340.6% | -292,0 k € | +63.7% | -804,7 k € | -312.3% | 379,0 k € | +497.2% | -95,4 k € | -109.8% | 974,3 k € | -3.6% | 1,0 M € | -49.5% | 2,0 M € | +60.0% | 1,3 M € | |
| Profit/loss | 7,6 M € | +21.9% | 6,2 M € | +1054.8% | 540,0 k € | -74.3% | 2,1 M € | -52.7% | 4,4 M € | +981.3% | 411,0 k € | -90.0% | 4,1 M € | +387.5% | -1,4 M € | +70.6% | -4,9 M € | -455.0% | 1,4 M € | +373.6% | 290,9 k € | +135.8% | -811,7 k € | -166.3% | 1,2 M € | +421.7% | 234,6 k € | -82.5% | 1,3 M € | -29.1% | 1,9 M € | +6.1% | 1,8 M € | -76.0% | 7,4 M € | |
| Equity | 113,2 M € | +75.3% | 64,6 M € | +10.7% | 58,3 M € | +0.9% | 57,8 M € | +40.1% | 41,2 M € | +12.1% | 36,8 M € | -12.1% | 41,9 M € | +10.9% | 37,8 M € | -3.7% | 39,2 M € | +143.6% | 16,1 M € | +9.4% | 14,7 M € | +2.0% | 14,4 M € | -5.3% | 15,2 M € | +8.7% | 14,0 M € | +1.7% | 13,8 M € | +10.8% | 12,4 M € | -6.1% | 13,2 M € | -6.4% | 14,1 M € | |
| Total assets | 144,8 M € | +60.7% | 90,1 M € | +4.2% | 86,5 M € | -2.9% | 89,0 M € | +42.0% | 62,7 M € | -0.7% | 63,1 M € | +15.9% | 54,5 M € | +5.1% | 51,8 M € | -13.7% | 60,0 M € | +57.7% | 38,1 M € | +32.7% | 28,7 M € | +5.2% | 27,3 M € | -3.2% | 28,2 M € | +0.4% | 28,1 M € | +10.3% | 25,4 M € | -6.4% | 27,2 M € | -6.5% | 29,1 M € | -0.0% | 29,1 M € | |
| Cash | 4,5 M € | +87.9% | 2,4 M € | -16.4% | 2,9 M € | -58.5% | 7,0 M € | +78.6% | 3,9 M € | -73.5% | 14,7 M € | +184.4% | 5,2 M € | +1962.8% | 250,7 k € | -58.6% | 605,9 k € | +2.5% | 591,1 k € | +56.7% | 377,3 k € | +17.5% | 321,2 k € | -24.6% | 426,0 k € | +49.2% | 285,5 k € | -79.5% | 1,4 M € | +24.3% | 1,1 M € | -57.9% | 2,7 M € | +43.1% | 1,9 M € | |
| Debts | 28,7 M € | +18.4% | 24,2 M € | -13.8% | 28,1 M € | -9.9% | 31,2 M € | +46.6% | 21,3 M € | -18.7% | 26,2 M € | +110.8% | 12,4 M € | -10.7% | 13,9 M € | -32.7% | 20,7 M € | -5.4% | 21,8 M € | +57.5% | 13,9 M € | +9.2% | 12,7 M € | -0.3% | 12,7 M € | -0.5% | 12,8 M € | +21.5% | 10,5 M € | -23.7% | 13,8 M € | -7.8% | 15,0 M € | +6.5% | 14,1 M € | |
| Staff | 127,2 | 101,9 | 100,2 | 107 | 85,5 | 70,2 | 65,9 | 70,7 | 76 | 74,3 | 69,7 | 71,3 | 69,3 | 69,6 | 65,1 | 64,6 | 59,1 | 54 | ||||||||||||||||||
Public limited company · Gent · incorporated on 20/10/1972 · 127,2 ETP
Public limited company profitable and well capitalised. Cash position rising (+87.9%).
Solid counterparty for a standard engagement.
Nuscience Belgium is a Public limited company incorporated in 1972. Its main activity is: Manufacture of prepared feeds for farm animals. Its registered office is in Gent. It employs on average 127,2 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette